文献速递造血干细胞移植与细胞治疗

IFN-λ治疗可预防严重胃肠道移植物抗宿主病

IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease.
PubMed 文献 · Blood · 2021-01-01

该研究在小鼠同种异体骨髓移植模型中揭示,干扰素-λ(IFN-λ;IL-28/IL-29)是胃肠道GVHD免疫病理的关键保护因子,尤其作用于肠道干细胞(ISC) compartment。Ifnlr1-/-小鼠表现出加重的GI GVHD和死亡率,且不依赖Paneth细胞和微生物组改变。PEG化重组IL-29(PEG-rIL-29)治疗可增强Lgr5+ ISC数量与类器官生长,改善BMT后生存、减轻GVHD严重程度并促进上皮增殖。

要点

  • IFN-λ信号缺失加重胃肠道GVHD和死亡率,与Paneth细胞及微生物组无关。
  • PEG-rIL-29可增加Lgr5+肠道干细胞数量并促进类器官生长。
  • PEG-rIL-29治疗改善BMT后生存、减轻GVHD并增强上皮增殖。

核心结论

  • IFN-λ是胃肠道GVHD免疫病理的关键保护因子,尤其保护肠道干细胞 compartment。
  • PEG-rIL-29治疗可改善BMT后生存、减轻GVHD严重程度并促进上皮增殖和ISC来源类器官生长。

研究设计与样本

  • 研究使用Ifnlr1-/-小鼠、肠道类器官及同种异体骨髓移植(BMT)模型。
  • 采用PEG化重组IL-29(PEG-rIL-29)处理naive小鼠及BMT后小鼠。
  • 通过靶向Ifnlr1缺陷评估受体Lgr5+ ISC和自然杀伤细胞的内在效应。

主要发现

  • Ifnlr1-/-小鼠出现加重的胃肠道GVHD和死亡率,独立于Paneth细胞和微生物组改变。
  • Ifnlr1-/-肠道类器官生长显著受损。
  • PEG-rIL-29处理naive小鼠增加Lgr5+ ISC数量并促进类器官生长,独立于IL-22和I型IFN。
  • PEG-rIL-29调节Lgr5+ ISC中的增殖和凋亡基因集。
  • BMT后PEG-rIL-29治疗改善生存、减轻GVHD严重程度并增强上皮增殖和ISC来源类器官生长。

临床怎么用

  • IFN-λ信号通路可作为预防胃肠道GVHD中ISC丢失和免疫病理的潜在治疗靶点。
  • PEG-rIL-29是可在临床前模型中快速测试的干预手段。

局限性

  • 研究基于小鼠模型,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunopathology and intestinal stem cell (ISC) loss in the gastrointestinal (GI) tract is the prima facie manifestation of graft-versus-host disease (GVHD) and is responsible for significant mortality after allogeneic bone marrow transplantation (BMT). Approaches to prevent GVHD to date focus on immune suppression. Here, we identify interferon-λ (IFN-λ; interleukin-28 [IL-28]/IL-29) as a key protector of GI GVHD immunopathology, notably within the ISC compartment. Ifnlr1-/- mice displayed exaggerated GI GVHD and mortality independent of Paneth cells and alterations to the microbiome. Ifnlr1-/- intestinal organoid growth was significantly impaired, and targeted Ifnlr1 deficiency exhibited effects intrinsic to recipient Lgr5+ ISCs and natural killer cells. PEGylated recombinant IL-29 (PEG-rIL-29) treatment of naive mice enhanced Lgr5+ ISC numbers and organoid growth independent of both IL-22 and type I IFN and modulated proliferative and apoptosis gene sets in Lgr5+ ISCs. PEG-rIL-29 treatment improved survival, reduced GVHD severity, and enhanced epithelial proliferation and ISC-derived organoid growth after BMT. The preservation of ISC numbers in response to PEG-rIL-29 after BMT occurred both in the presence and absence of IFN-λ-signaling in recipient natural killer cells. IFN-λ is therefore an attractive and rapidly testable approach to prevent ISC loss and immunopathology during GVHD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Henden AS, Koyama M, Robb RJ, et al. IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease. Blood. 2021. PMID: 34436524. doi:10.1182/blood.2020006375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。